` MSB (Mesoblast Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

MSB
vs
S&P/ASX 300

Over the past 12 months, MSB has significantly outperformed S&P/ASX 300, delivering a return of 58% compared to the S&P/ASX 300's 9% growth.

Stocks Performance
MSB vs S&P/ASX 300

Loading
MSB
S&P/ASX 300
Add Stock

Performance Gap
MSB vs S&P/ASX 300

Loading
MSB
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
MSB vs S&P/ASX 300

Loading
MSB
S&P/ASX 300
Add Stock

Competitors Performance
Mesoblast Ltd vs Peers

S&P/ASX 300
MSB
ABBV
AMGN
GILD
VRTX
Add Stock

Mesoblast Ltd
Glance View

Market Cap
2B AUD
Industry
Biotechnology

Mesoblast Ltd., a biotechnology company based in Australia, is navigating the frontier of regenerative medicine with its innovative approach to cell therapy. Founded in 2004, Mesoblast has carved a niche for itself by concentrating on the development and commercialization of allogeneic cellular medicines derived from mesenchymal lineage adult stem cells. These stem cells are pivotal in regenerative therapy due to their remarkable ability to differentiate, reduce inflammation, and promote tissue repair. Mesoblast harnesses this potential to address critical medical conditions, including cardiovascular diseases, spine diseases, immune-mediated diseases, and some rare pediatric conditions. By developing proprietary technology, the company aims to produce off-the-shelf therapies that can be readily available to patients, avoiding the complexities and delays often associated with personalized cellular therapies. The company’s revenue model hinges on the development of its extensive pipeline of products, with an eye towards capturing significant market opportunities across multiple therapeutic areas. Revenues are primarily anticipated from three avenues: collaborations with major pharmaceutical companies, licensing agreements, and, eventually, product sales upon regulatory approval. Mesoblast's strategic partnerships often involve substantial upfront payments, milestone payments, and royalties on the sale of licensed products. For instance, collaborations with giants like Grunenthal in Europe have fortified its research and funding capabilities. Meanwhile, Mesoblast is also committed to expanding its product commercialization capabilities to strategically manage its transition from a research-centered entity to a biopharmaceutical pioneer with marketed therapies. This dual-focused strategy aspires to deliver shareholder value while advancing the horizons of medical treatment.

MSB Intrinsic Value
1.116 AUD
Overvaluation 29%
Intrinsic Value
Price
Back to Top